eyeforpharma is now Reuters Events - LEARN MORE
Trends in Real-World Evidence
Is data the new oil?
It has much in common – it must be found and extracted, cleaned and refined, then transported to its final destination – with challenges at every point along that journey. Real-world evidence may be seen as a key fuel to power pharma’s next evolution but it is no simple silver bullet.
Where does the data come from? How reliable is the data? Can pharma even access the best data? Then there’s the analysis – how can pharma ensure that payers trust its analyses? Will payers seek to perform their own analyses, or will they increasingly turn to a third party? If so, which review body will become the most trusted source?
In the latest edition of our Trends magazine, we offer insights senior data leaders from UCB, Janssen, Merck and AstraZeneca.
Please subscribe to view the analysis report